Skip to main content
Clinical Trials/NCT06304870
NCT06304870
Not yet recruiting
Not Applicable

Impact of Blocking the Glossopharyngeal Nerve on Gastroesophageal Reflux Disease: A Randomized Double-blind Controlled Study

Muhammad0 sites80 target enrollmentMarch 2024

Overview

Phase
Not Applicable
Intervention
Rehabilitation therapy
Conditions
Dysphagia
Sponsor
Muhammad
Enrollment
80
Primary Endpoint
Rosenbek penetration-aspiration scale
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this clinical trial is to explore Clinical Effect of Glossopharyngeal Nerve Block on Pharyngeal Dysphagia Induced by Gastroesophageal Reflux Disease. The main question it aims to answer is:

• Can Glossopharyngeal Nerve Block improve dysphagia caused by gastroesophageal reflux symptoms on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Glossopharyngeal Nerve Block once a day additionally. The study lasts 20 days for each participant. Researchers will compare the Rosenbek penetration-aspiration scale, Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, to see if the Glossopharyngeal Nerve Block can help improve the symptom.

Detailed Description

Gastroesophageal reflux is a common digestive disorder characterized by the backflow of stomach contents and fluids into the esophagus. The goal of this clinical trial is to explore Clinical Effect of Glossopharyngeal Nerve Block on Pharyngeal Dysphagia Induced by Gastroesophageal Reflux Disease. The main question it aims to answer is: • Can Glossopharyngeal Nerve Block improve dysphagia caused by gastroesophageal reflux symptoms on the basis of rehabilitation training? Participants will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Glossopharyngeal Nerve Block once a day additionally. The study lasts 20 days for each participant. Researchers will compare the Rosenbek penetration-aspiration scale, Gastroesophageal Reflux Disease Questionnaire, Pressure pain threshold, to see if the Glossopharyngeal Nerve Block can help improve the symptom.

Registry
clinicaltrials.gov
Start Date
March 2024
End Date
June 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Muhammad
Responsible Party
Sponsor Investigator
Principal Investigator

Muhammad

Research Director

Ahmadu Bello University Teaching Hospital

Eligibility Criteria

Inclusion Criteria

  • Meeting the diagnostic criteria for Gastroesophageal Reflux Disease.
  • Age between 18 and 65 years.
  • Confirmed tongue-pharyngeal nerve injury by electromyography.
  • Esophageal manometry and barium swallow examination confirming the presence of pharyngeal dysphagia.
  • Normal higher brain function, able to cooperate with treatment.

Exclusion Criteria

  • Brain vascular disease diagnosed.
  • Clinical assessment and swallowing videofluoroscopic examination revealing cognitive phase, oral preparatory phase, or oral phase disorders.
  • Concurrent presence of other neurological disorders such as Alzheimer's disease, traumatic brain injury, Parkinson's disease.
  • Esophageal obstruction and severe liver or kidney dysfunction
  • Subjective unwillingness to undergo the treatment and presence of psychiatric abnormalities, etc.

Arms & Interventions

Rehabilitation therapy+Placebo Glossopharyngeal Nerve Block

The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy and placebo nerve block.

Intervention: Rehabilitation therapy

Rehabilitation therapy+Placebo Glossopharyngeal Nerve Block

The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy and placebo nerve block.

Intervention: Injection

Rehabilitation therapy+Glossopharyngeal Nerve Block

The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.

Intervention: Rehabilitation therapy

Rehabilitation therapy+Glossopharyngeal Nerve Block

The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.

Intervention: Lidocaine

Rehabilitation therapy+Glossopharyngeal Nerve Block

The study lasts 20d for each patient. During the treatment, All the participants are provided with the rehabilitation therapy. Based on this, the patients in the experimental group are provided with Stellate Ganglion Block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g), once a day.

Intervention: Injection

Outcomes

Primary Outcomes

Rosenbek penetration-aspiration scale

Time Frame: day 1 and day 20

This assessment evaluated the patient's swallowing of contrast medium and whether there was retention, penetration, and aspiration. It included multiple items, each with the corresponding criteria, Specifically, whether the swallowed material entered the airway, passed through or contacted the vocal cords, and whether the patient exhibited the corresponding ability to clear. There were 8 levels in the results, with higher levels indicating more severe aspiration.

Secondary Outcomes

  • Gastroesophageal Reflux Disease Questionnaire(day 1 and day 20)
  • Pressure pain threshold(day 1 and day 20)

Similar Trials